Archive — US — techcrunch
NewLimit, founded by Coinbase CEO Brian Armstorng, raises $130M to developage-reversing treatments
NewLimit, co-founded by Coinbase CEO Brian Armstrong, secured $130M in a Series B round for age-reversing treatments focusing on genetic cell programming. The startup has developed prototypes that rejuvenate liver cells, enhancing their ability to process nutrients. They plan to use AI for drug development and anticipate human trials in a few years, joining the growing biotech trend for longevity enhancements.
Key points
- NewLimit raised $130M in Series B led by Kleiner Perkins, with participation from notable investors like Nat Friedman and Khosla Ventures.
- The company aims to develop treatments to reverse aging by genetically programming cells.
- They claim to have made significant advancements, discovering three prototype medicines that reprogram liver cells.
- Lab experiments indicate that reprogrammed older liver cells can function more like younger cells.
- NewLimit is several years away from human trials but plans to use AI for developing and testing age-reversing medicines.
Why it matters
- The trend in biotech to explore longevity through genetic programming aligns with increasing investments in health-tech.
- Concurrent developments in the field include Retro Biosciences and Altos Labs, which also focus on lifespan enhancement.
- The integration of AI in drug discovery is becoming prevalent, influencing the pace and efficacy of medical research.
NewLimit's recent funding showcases the surge in biotech dedicated to anti-aging, with innovative approaches like AI-driven drug development, marking a significant moment in the quest for longer, healthier lives.